ACAD
ACADIA Pharmaceuticals Inc
ACADIA Pharmaceuticals Inc historical holders
total: 2
Thunderbird Partners ACADIA Pharmaceuticals Inc transactions over time
- Total transactions:
- 2
- New positions:
- 1
- Sold out:
- 1
- Held since:
- 2022 Q1
- Held for:
- 1 quarter
- Latest activity:
- 2022 Q2
David Jeffrey Fear has been an institutional investor in ACADIA Pharmaceuticals Inc (ACAD) since 2022 Q1. According to 2026 Q1 report, David Jeffrey Fear doesn't hold any shares. The fund/company first acquired ACAD in 2022 Q1, initially purchasing 692,825 shares. Since the initial investment, Thunderbird Partners has made 1 more transaction in this position.
When did David Jeffrey Fear exit their ACAD position?
David Jeffrey Fear no longer holds ACADIA Pharmaceuticals Inc (ACAD). They sold off their entire position in 2022 Q2, closing out an investment that began in 2022 Q1.
When did David Jeffrey Fear first invest in ACAD?
David Jeffrey Fear first invested in ACADIA Pharmaceuticals Inc (ACAD) in 2022 Q1 at the reported quarter-end price of $24.22 per share, acquiring 692,825 shares in their initial purchase.
What is David Jeffrey Fear's average cost basis for ACAD?
Based on historical transaction data, David Jeffrey Fear's estimated cost basis for ACADIA Pharmaceuticals Inc (ACAD) is approximately $24.22 per share. This represents their average reported price* across all buy transactions.
Estimated cost basis*
- Weighted AVG buy price:
- $24.22
- Weighted AVG sell price:
- $24.22
ACAD transactions history by Thunderbird Partners
2 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2022 Q2
|
0.00%
|
0
|
$24.22
|
|
-100% (-692,825)
|
-2.38%
|
|
2022 Q1
|
2.38%
|
692,825
|
$24.22
|
$16,780,000
|
new
|
+2.38%
|
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.